KKDIK and Consortiums: Why MBDF, LoA and REACH Data Sharing Matter in Türkiye

The role of consortiums in KKDIK registration

KKDIK is Türkiye’s framework for the registration, evaluation, authorisation and restriction of chemicals. For many substances placed on the Turkish market at one tonne or more per year, registration is not optional unless a specific exemption applies.

As the calendar moves toward 30 September 2026 — a key milestone for interim (provisional) registration — companies are also planning what happens next: full registration, MBDF positioning, LoA coverage and whether REACH-type consortium logic is in place for their substances.

Substances without a credible interim (provisional) or full registration number after relevant deadlines can face commercial continuity risk: customs questions, importer reluctance, customer audits and supply-chain disruption. Consortium and data-sharing discipline is therefore not only a cost topic — it is a market-access topic.

What is a consortium?

A consortium brings together companies that share registration obligations for the same substance or substance group to coordinate:

• technical dossier development
• study and data costs
• LoA / Letter of Access negotiation
• lead registrant support
• updates when regulation or data requirements change

Consortiums are well established under EU REACH. Under KKDIK, similar coordination is increasingly necessary because the same substance may be imported by several Turkish entities, supplied by non-Turkish manufacturers, or registered through different commercial routes.

A consortium is not a public authority. It is typically organised by companies, sector associations or data owners under private contractual rules.

Why are consortiums needed?

Sharing data costs

Toxicology and environmental studies are expensive. Sharing costs across registrants is often the only commercially realistic way to complete a robust dossier.

Avoiding duplicate testing

Without coordination, companies may commission redundant tests for the same substance — wasting budget and increasing animal testing where alternatives exist.

Reducing animal testing

Shared data strategies, where legally and technically justified, support 3Rs principles and align with how REACH SIEF/consortium practice evolved.

Managing a joint registration dossier

Someone must maintain version control, IUCLID/KKS logic, updates and consistency between members.

Supporting the lead registrant

The lead registrant carries significant technical and coordination load. A consortium can fund and govern that role transparently.

Organising LoA / Letter of Access processes

LoA terms (scope, updates, cost allocation, dispute resolution) are easier to manage in a structured consortium than ad hoc between strangers in MBDF.

Tracking dossier updates and regulatory change

When classification, uses or legal requirements shift, members need a channel to receive updates and implement them.

Fair, transparent and non-discriminatory cost sharing

Well-run consortiums document cost rules upfront — reducing later conflict between lead registrant and co-registrants.

What is MBDF and how is it different from a consortium?

MBDF (in KKDIK practice, analogous to SIEF thinking under EU REACH) is the communication and data-sharing space for potential registrants of the same substance. It helps parties:

• identify each other
• discuss data availability
• agree on data-sharing principles
• progress toward joint or aligned registration

MBDF is not a consortium. MBDF is primarily a regulatory communication forum. A consortium is a more formal contractual and operational structure: budgets, LoA templates, lead election, governance and long-term dossier maintenance.

Companies should run Pre-MBDF / MBDF early — not after interim (provisional) deadlines — and align MBDF outcomes with consortium contracts where needed. See our article on Pre-MBDF vs provisional registration.

Lead registrant and co-registrant roles

The lead registrant typically:

• prepares and maintains the core technical dossier
• interacts with MBDF participants on data gaps
• manages update cycles and technical consistency

Co-registrants (member registrants) join with:

• their tonnage band for Türkiye
• use and exposure information
• importer/downstream user mapping where relevant

Even with a lead, each company remains responsible for its KKDIK compliance. Assuming “the lead will handle everything” is one of the most common planning failures.

What is a Letter of Access?

A Letter of Access (LoA) grants the right to cite or use existing studies or the joint dossier in your registration. It is usually:

• a use/reference right, not necessarily ownership transfer
• limited by scope (substance identity, endpoints, territories, registration type)
• linked to cost and update obligations

For KKDIK, you must verify that LoA language covers Turkish registration — not only EU REACH.

Can EU REACH data be used for KKDIK?

Sometimes yes — but only with proper rights. Studies used in an EU REACH dossier may be reusable in KKDIK if the data owner or consortium grants permission through:

• LoA
• licence to use
• another data-use agreement

The risky assumption is: “We are REACH-registered, so KKDIK data is solved.” That is rarely true without written confirmation for the Turkish context.

Substance identity must go beyond a CAS number alone — impurities, forms and supply chains matter.

Common mistakes companies make

• Treating an EU REACH LoA as automatically valid for KKDIK
• Relying on CAS alone for substance identity
• Starting MBDF communication too late
• Expecting the lead registrant to manage all legal and commercial issues alone
• Clarifying the Turkish importer chain too late
• Running SEA/CLP, Pre-MBDF and registration strategy in silos
• Failing to obtain written data ownership / use documents
• Planning interim (provisional) registration separately from full registration and LoA strategy

The role of consortiums in interim (provisional) registration

Interim (provisional) registration does not remove full registration duties. It buys time and continuity while you:

• stabilise MBDF membership
• secure LoA positions
• confirm whether a lead registrant is viable
• align with interim registration deadlines including 30 September 2026

After that milestone, substances without a defensible interim (provisional) or full registration position may face supply-chain pressure. Consortium planning should therefore start before the last administrative weeks.

How Pier Compliance can support your KKDIK strategy

Pier Compliance provides end-to-end support on:

• KKDIK obligation and applicability analysis
• substance identity and tonnage assessment
• Turkish importer-chain analysis
• Pre-MBDF and MBDF process management
• SEA/CLP notification (guide)
• lead registrant / co-registrant strategy
• LoA and data-access review
• EU REACH data usability for KKDIK
• interim (provisional) registration dossier preparation
• full registration strategy
• Only Representative services
• SDS preparation aligned with registration outputs

We also support adjacent programmes where relevant — for example EU REACH compliance and biocidal product authorisation — when portfolio scope requires it.

Conclusion

KKDIK consortiums are not only about splitting invoices. They protect technical quality, legal certainty, data access and continuity on the Turkish market. Firms that delay MBDF, LoA or lead registrant decisions often discover gaps only when customers or customs ask for proof.

Pier Compliance supports companies with KKDIK, MBDF, LoA, interim (provisional) registration, full registration and Only Representative services. Contact Pier Compliance at info@piercompliance.com to assess your obligations in Türkiye and build a reliable registration strategy. Explore our KKDIK service page for scope details.